Predicting imminent cognitive decline among unimpaired older adults with digital cognitive testing and Alzheimer's disease blood‐based biomarkers

Abstract

Background: Identifying clinically unimpaired individuals at greatest risk for short‐term cognitive decline related to Alzheimer's disease is critical for early intervention. Doing so with a combination of remote digital cognitive testing and blood‐based AD biomarkers would be an efficient and cost‐effective approach.